In Brief City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers April 24, 2026Vol.52 No.16
In Brief IU Cancer Center Chuckstrong Tailgate Gala raises more than $900,000 April 24, 2026Vol.52 No.16
In Brief The Cancer Letter’s Claire Marie Porter wins 1st place in Association of Health Care Journalists 2025 awards April 24, 2026Vol.52 No.16
Clinical Roundup CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study April 24, 2026Vol.52 No.16
Clinical Roundup Johns Hopkins-led study shows how bacterial toxin drives colon tumor formation April 24, 2026Vol.52 No.16
Drugs & Targets FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer April 24, 2026Vol.52 No.16
Drugs & Targets EU approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration April 24, 2026Vol.52 No.16
Health EquityRegulatory News Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancerA kit for at-home unsupervised self-collection clears FDA finish line April 17, 2026Vol.52 No.15By Claire Marie Porter
Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” April 17, 2026Vol.52 No.15By Jacquelyn Cobb
